Organization Profile
Humanity’s health needs, are greater than any one company’s ability to address them; yet we can work with others to bring new drugs quickly to the market and provide the building blocks of affordable medicines.
Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company. As a fully integrated pharmaceutical company, our purpose is to provide affordable and innovative medicines through our three core businesses:
- Pharmaceutical Services and Active Ingredients (PSAI), comprising our Active Pharmaceuticals and Custom Pharmaceuticals businesses;
- Global Generics, which includes branded and unbranded generics; and
- Proprietary Products, which includes New Chemical Entities (NCEs), Differentiated Formulations, and Generic Biopharmaceuticals. Our products are marketed globally, with a focus on India, US, Europe and Russia.
Pharmaceutical Services and Active Ingredients
Through our PSAI business, we offer Intellectual Property (IP) advantaged, speedy product development and cost-effective manufacturing services to our customers – generic companies and innovators. This allows us to help make good medicines available to more people around the world. The core strengths of our PSAI business are the state-of-the-art infrastructure, resources and relevant skills we are able to offer to our customers, such as
- Large and diverse product portfolio
- Eight FDA-inspected plants and three technology centers
- World class chemistry expertise
- Robust, large-scale manufacturing capabilities
- IP driven product development for freedom to operate
- Total, seamless supply chain management
Both, in the developing and developed world, it is a grim fact that millions of people suffer from treatable illnesses and disease simply because they cannot afford the medicines that will restore them to health. Even in high income countries like the US, brand name drugs are often prohibitively expensive, particularly for the growing numbers of uninsured. Around the world, having access to lower-cost generic medicines can mean the difference between health and sickness, solvency and bankruptcy for countless people.
Generic drugs hold great promise for the future. The growing acceptance of generics and favorable legislation in many geographies, combined with the large volume of branded products losing patent protection over the years, is expanding the generic pharmaceuticals market.
Through our branded and unbranded Global Generics business, we fulfill our purpose of providing affordable medicines to more people around the world by offering lower-cost alternatives to highly-priced innovator brands, both directly and through key partnerships.
Our capabilities span the entire value chain – from process development of the Active Pharmaceutical Ingredient (API) to submission of the finished dosage dossier, to the regulatory agencies – giving us control over the supply chain and the ability, to offer high quality products at the right time and at competitive prices. Our state-of-the-art manufacturing facilities are ISO14001 and ISO9001 certified and have an excellent record of regulatory compliance. Our Generics business is supported by our integrated Product Development Infrastructure, which identifies new products and significantly reduces the time between concept and delivery of medicines to market.
Today, we have a strong presence both in highly regulated markets like the US, UK, and Germany and in the emerging markets of India and Russia. We are building our presence in other emerging markets of Venezuela, Romania, and CIS (Belarus, Ukraine and Kazakhstan).
Proprietary Products
Science and innovation hold the key to unlocking the mysteries of diseases that continue to afflict humanity. While scientific advances have either obliterated many deadly diseases or brought them under control, there are still far too many diseases that lack satisfactory treatments or cures. These unmet medical needs of humanity drive our research enterprise.
Our Proprietary Products business comprises NCE research, Biologics and Differentiated Formulations. In each of these areas, we are building world-class capabilities and partnerships to accelerate the discovery and development of new and improved therapies.
Within our integrated R&D infrastructure, scientists with diverse functional expertise seek innovative solutions to medical needs in the therapeutic areas of metabolic diseases, anti-infectives and inflammatory diseases. Our scientific capabilities span a wide range of areas, such as medicinal chemistry, analytical chemistry, pharmacology, genomics, proteomics, molecular biology, microbiology, toxicology, formulation and clinical development.
People
11000+ Employees
2000+ at International Locations
3800+ Marketing & Sales Force
3700+ Manufacturing Staff
1200+ Research & Scientific Personnel
Affiliations
- Drugs Technical Advisory Board (DTAB)
- Indian Institute of Public Health
- The Energy Research Institute (TERI)
- Business Council for Sustainable Development (BCSD) in India – Indian regional network partner of WBCSD
- Confederation of Indian Industry (CII)
- Indian Pharmaceutical Alliance (IPA)
- The Conference Board
- SustainAbility, UK
- World Wide Fund, India
- Acumen Fund
- Young Presidents Organization Forum
Headquartered in Hyderabad, India, we have a global presence and an extensive marketing network through international subsidiaries, marketing partners and joint ventures. Our global presence leads to a sensitive understanding of the local laws in the countries where our Company has operations.
With the marketing deal signed with GSK in June 2009, we now have the power of around seven thousand sales representatives of GSK in the emerging markets, through which our products would flow to patients everywhere around the globe.
- Global commercialization infrastructure with a focus on US, Europe, India, and Russia
- Manufacturing locations in India, UK, US, China and Mexico
- Research and development locations in India and UK
- Wholly-owned subsidiaries in the US, UK, Russia, Germany and Brazil
- Joint Ventures in China, South Africa and Australia
- 83% of revenues in GY 09 came from geographies outside India
Pharmaceutical Services & Active Ingredients
- 6 FDA-inspected plants in India
- 1 Cytotoxic facility included
- 1 FDA-inspected plant in Mexico
- 1 FDA-inspected plant in Mirfield, UK
- 3 technology development centers
- 2 in Hyderabad, India; 1 in Cambridge, UK
- 6 Finished Dosage plants (5 in India, 1 in USA)
- The largest USFDA inspected plant in Asia (in capacity)
- 1 Innovation Plaza to house the Integrated Product Development capabilities
- API development, Finished Dosage development and analytical development skills
- Facility in Hyderabad, India
- 2 research centers in India conduct research in the areas of metabolic disorders
- 1 Biologics development center
- GMP production, E coli and mammalian cell platforms
- Among the leading global pharmaceutical companies from India
- 5th largest branded generic player in Germany
- Ranked 7th in the retail segment in Russia, the largest player from India
- Among the Top Ten generic companies in India
- Among Top 3 API players globally
- Top 3 ANDA and DMF pipeline in the USA
- Among the largest players in the Custom Pharmaceutical Services (CPS) segment
- 4th on Environment & Social Governance Index, India
- Best Workplace in Pharma & Biotech - Great Place to Work 2009
- Best Workplace in Pharma & Biotech - Great Place to Work 2008
- The fastest path to USD 1 billion in revenues amongst Indian Pharma companies
Corporate Address
Dr. Reddy's Laboratories Ltd.Greenlands, Ameerpet,
Hyderabad 500 016, INDIA
Tel: +91-40-23731946/47/48/49/50
Fax: +91-40-23731955
Visit: www.drreddys.com
Font Size
© 2001 - 2009 Dr. Reddy's Laboratories Ltd.
Best viewed in 1024x780 resolution